Health Trials

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

ConditionProstatic Neoplasms, Castration-Resistant
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorClarity Pharmaceuticals Ltd

About this trial

The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

Eligibility criteria

Qualifiers

Signed informed consent;

≥18 years of age;

Eastern Cooperative Oncology Group performance status of 0 to 2;

Life expectancy >6 months;

Disqualifiers

Major surgery within 12 weeks prior to enrollment into the study;

Brain metastasis;

Histologic diagnosis of small cell or neuroendocrine prostate cancer;

Prior history of leukemia or Myelodysplastic Syndrome;

Trial design

Treatments tested in this trial

  • 64Cu-SAR-bisPSMA
  • 67Cu-SAR-bisPSMA

Treatment groups

54 Participants
are divided into 1 treatment group

Sponsors and collaborators

Clarity Pharmaceuticals Ltd

Lead sponsor

Source ClinicalTrials.gov